Absorption of erythromycin. A cross-over study in healthy volunteers. 1975

P Männistö, and J Tuomisto, and R Räsänen

The absorptions of 6 erythromycin preparations were compared in a cross-over study in healthy humans. In a single-dose study, 500 mg of each preparation was, after an overnight fast, given to 10 volunteers. The two enterosoluble preparations of erythromycin base studied were absorbed slowly, and the peak serum concentration (1.5-2 mg/l) was achieved only at 4 h. The absorption of the stearates was quick, but especially one of them was poorly absorbed, the serum concentration being always below 1 mg/l. Both of the two estolates gave highest apparent concentrations, and the maximum serum level (2-2.5 mg/l) was achieved at 2 h, but the concentration of active erythromycin remains unknown. In the second part of the study, two erythromycin stearates and one base preparation were given at 6-h interval in a cross-over fashion, each for 4 days. On the 4th day, blood samples were analyzed. The erythromycin base gave higher serum concentrations than did the two stearates, which were equivalent. It seems doubtful that the erythromycin stearate at the dose of 250 mg every 6th hour would give satisfactory serum levels of erythromycin which would be effective against most bacteria during the whole treatment.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D004918 Erythromycin Estolate A macrolide antibiotic, produced by Streptomyces erythreus. It is the lauryl sulfate salt of the propionic ester of erythromycin. This erythromycin salt acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin Propionate Dodecyl Sulfate,Erythromycin Propionate Lauryl Sulfate,Eromycin,Erythromycin Propionate Monododecyl Sulfate,Ilosone,Lauromicina,Estolate, Erythromycin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001702 Biopharmaceutics The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action. Pharmaceutics,Pharmaceutic
D013607 Tablets Solid dosage forms, of varying weight, size, and shape, which may be molded or compressed, and which contain a medicinal substance in pure or diluted form. (Dorland, 28th ed) Tablet
D013608 Tablets, Enteric-Coated Tablets coated with material that delays release of the medication until after they leave the stomach. (Dorland, 28th ed) Enteric-Coated Tablets,Tablets, Enteric Coated
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

P Männistö, and J Tuomisto, and R Räsänen
January 1985, European journal of clinical pharmacology,
P Männistö, and J Tuomisto, and R Räsänen
January 1989, International journal of clinical pharmacology research,
P Männistö, and J Tuomisto, and R Räsänen
April 2006, Journal of thrombosis and haemostasis : JTH,
P Männistö, and J Tuomisto, and R Räsänen
September 2016, European journal of anaesthesiology,
P Männistö, and J Tuomisto, and R Räsänen
October 2015, Acta anaesthesiologica Scandinavica,
P Männistö, and J Tuomisto, and R Räsänen
April 1995, Pharmacology & toxicology,
P Männistö, and J Tuomisto, and R Räsänen
January 1983, European journal of clinical pharmacology,
P Männistö, and J Tuomisto, and R Räsänen
June 2020, Respiratory physiology & neurobiology,
P Männistö, and J Tuomisto, and R Räsänen
October 1987, Methods and findings in experimental and clinical pharmacology,
Copied contents to your clipboard!